Poster

The Effectiveness of using escitalopram in Pediatric GAD and the Methods to Predict the treatment response: a Systematic Review and Meta-analysis

this is the first Systematic review that discussed the use of the escitalopram in GAD in pediatric patients, regarding use, safety efficacy, and possible treatment prediction methods and ...

10/26/2023

The effects of Covid-19 on Health Insurance and Mental Health

Our hypothesis postulates that those who had employer-based insurance were negatively affected and those who had public insurance were positively affected. Those who were on public insura...

Andrew Kim , PhD, MPH;

10/26/2023

The Importance of Incorporating Drug-Drug Interactions and Lifestyle Factors in Pharmacogenomics-Guided Medication Management for Patients With Major Depressive Disorder in a Randomized Controlled Trial

IDgenetix is the only clinically validated pharmacogenomic test that combines drug-drug interactions (DDI) and lifestyle factors with drug-gene interactions and demonstrates improved outc...

Feng Cao , PhD;

10/26/2023

The Rapid Mood Screener (RMS) for Bipolar I Disorder: Study Design for a Confirmatory Study Evaluating Performance in Real-World Settings

This large, cross-sectional, observational study will be conducted in a sample reflecting bipolar I disorder prevalence in real-world settings to confirm the performance of the Rapid Mood...

Huy-Binh Nguyen ;

10/26/2023

Successful Buprenorphine/Naloxone High-dose Induction in Pregnancy

Medication for opioid use disorder (OUD) with methadone or buprenorphine/naloxone is recommended for pregnant women with OUD. Traditional buprenorphine/naloxone induction requires patient...

Arjun Bhatt , BA;

10/26/2023

SURWEY Study of Solriamfetol: Initiation, Titration, Safety, Efficacy, and Follow-Up Experience for Patients with OSA in Germany

This real-world study examined initiation strategies and subsequent outcomes for solriamfetol (Sunosi®), a wake-promoting agent used to treat excessive daytime sleepiness (EDS) in obstruc...

Charlotte Wincott , PhD;

10/26/2023

Sleep Disturbances Are Highly Predictive of Major Depressive Disorder Recurrence

This longitudinal study evaluated the impact of sleep disturbances, including hypersomnolence, on the progress of major depressive disorder (MDD) over a 3-year period. Participant charact...

Venkatesh Ganapathy , MD;

10/26/2023

SOLARIS Protocol: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Trial of TV-44749 for Subcutaneous Use (Olanzapine for Extended-Release Injectable Suspension Use) in Adults With Schizophrenia

Intramuscular long-acting injectable olanzapine is approved for treatment of schizophrenia in adults but has an associated risk for post-injection delirium/sedation syndrome. The Subcutan...

Kelli R. Franzenburg , PhD;

10/26/2023

Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea: Effect Sizes and Numbers Needed to Treat or Harm

This post-hoc analysis of two phase 3 studies demonstrates that solriamfetol, an approved treatment for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea, ...

Sean Hammond , PhD;

10/26/2023

Solriamfetol Improves Cognitive Performance in Preclinical Models of Sleep Apnea and in a Randomized Placebo-controlled Study of Sleep Apnea Participants (SHARP)

Solriamfetol is a dopamine-norepinephrine reuptake inhibitor (DNRI) that improves wakefulness in adults with EDS and OSA. Beyond inhibiting DAT/NET, solriamfetol demonstrated agonist acti...

Gregory Parks ;

10/26/2023